142 related articles for article (PubMed ID: 31617004)
1. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Crombag MBS; Koolen SLW; Wijngaard S; Joerger M; Dorlo TPC; van Erp NP; Mathijssen RHJ; Beijnen JH; Huitema ADR
Pharm Res; 2019 Oct; 36(12):163. PubMed ID: 31617004
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
4. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.
Crombag MBS; de Vries Schultink AHM; Koolen SLW; Wijngaard S; Joerger M; Schellens JHM; Dorlo TPC; van Erp NP; Mathijssen RHJ; Beijnen JH; Huitema ADR
Pharm Res; 2019 Jan; 36(2):33. PubMed ID: 30617624
[TBL] [Abstract][Full Text] [Related]
5. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
[TBL] [Abstract][Full Text] [Related]
6. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
[TBL] [Abstract][Full Text] [Related]
9. A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.
Mendes MS; Hatley O; Gill KL; Yeo KR; Ke AB
Eur J Pharm Sci; 2020 Jul; 150():105355. PubMed ID: 32438273
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
[TBL] [Abstract][Full Text] [Related]
11. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.
Henrich A; Joerger M; Kraff S; Jaehde U; Huisinga W; Kloft C; Parra-Guillen ZP
J Pharmacol Exp Ther; 2017 Aug; 362(2):347-358. PubMed ID: 28600397
[TBL] [Abstract][Full Text] [Related]
12. [Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):815-9. PubMed ID: 11432350
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.
Ait-Oudhia S; Straubinger RM; Mager DE
Pharm Res; 2012 Oct; 29(10):2833-44. PubMed ID: 22588463
[TBL] [Abstract][Full Text] [Related]
14. Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.
Ishikawa M; Kawai M; Maeda T; Kagawa Y
Cancer Chemother Pharmacol; 2018 Feb; 81(2):399-411. PubMed ID: 29299638
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.
Fetterly GJ; Tamburlin JM; Straubinger RM
Biopharm Drug Dispos; 2001 Sep; 22(6):251-61. PubMed ID: 11754041
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
20. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Sissung TM; Mross K; Steinberg SM; Behringer D; Figg WD; Sparreboom A; Mielke S
Eur J Cancer; 2006 Nov; 42(17):2893-6. PubMed ID: 16950614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
